Skip to main content
Hauptrubriken
CME Facharzt-Training Webinare Zeitschriften Bücher e.Medpedia Podcast
Service
Jobbörse Info & Hilfe
Fachgebiete
Anästhesiologie Allgemeinmedizin Arbeitsmedizin Augenheilkunde Chirurgie Dermatologie Gynäkologie und Geburtshilfe HNO Innere Medizin Kardiologie Neurologie Onkologie und Hämatologie Orthopädie und Unfallchirurgie Pädiatrie Pathologie Psychiatrie Radiologie Rechtsmedizin Urologie Zahnmedizin
Themen
Klimawandel und Gesundheit Neues aus dem Markt COVID-19 Praxis und Beruf Seltene Erkrankungen GOÄ & EBM Panorama
Sammlungen
Kasuistiken Algorithmen & Infografiken Blickdiagnosen Arthropedia FlapFinder (für Dermatochirurgen) Videos Kongressberichterstattung Medizin für Apothekerinnen und Apotheker Für Ärztinnen und Ärzte in Weiterbildung Für Medizinstudierende

Live-Webinar: Aktuelle Leitlinien bei Herz-Kreislauf-Erkrankungen

Konkret geht es um den Diabetes-Patienten mit kardiovaskulären Erkrankungen oder Risiken, die Herzinsuffizienz sowie die kardiovaskuläre Primär- und Sekundärprävention. Sind Sie hier schon auf dem neuesten Stand? Unsere Experten beleuchten, wo und warum das bisherige Procedere geändert werden soll und was in der Praxis sinnvoll ist. Holen Sie sich Ihr Update und 2 CME-Punkte beim MMW-Webinar am 24. April von 17.30 bis 19 Uhr. 
Erweiterte Suche
Anmelden
nach oben
International Journal of Diabetes in Developing Countries
Erschienen in: International Journal of Diabetes in Developing Countries 3/2014

01.09.2014 | Original Article

The effect of the intracerebroventricular injection of Ghrelin agonist on diabetes type 2 disease in male wistar rats

verfasst von: Alieh Safamanesh, Ramesh Ahmadi, Elham Safarpour Kapurchal, Arezou Ghahghaei

Erschienen in: International Journal of Diabetes in Developing Countries | Ausgabe 3/2014

Einloggen, um Zugang zu erhalten

Abstract

Ghrelin, a peptide hormone, synthesized in the stomach, has an effect on glucose metabolism and on blood pressure. The aim of this study is to investigate the effect of an exogenous ghrelin agonist in patients with type 2 diabetes. Three groups of rats were studied: control, sham and experimental (N = 6). After ascertaining that there were diabetic rats in both the control and experimental groups, a dose of 3nM of ghrelin agonist and normal saline was injected through a cannula into the right ventricle in the rats in the experimental and control groups. The results showed a decrease in serum glucose in the experimental group compared to the first day. This difference is comparable between the experimental (*P ≤ 0.05) and the sham group. It is concluded that the injection of a ghrelin agonist (3nM) probably reduces glucose-induced secretion by the pancreatic islets. Under physiological conditions, therefore, ghrelin agonist may modulate the secretion of insulin.
Literatur
1.
Maassen JA, ‘T Hart LM, Van Essen E, Heine RJ, Nijpels G, Jahangir Tafrechi RS, et al. Mitochondrial Diabetes, Molecular Mechanisms and Clinical Presentation. Diabetes. 2004;53:103–9.CrossRef
2.
Ceriello A. Perspectives in Diabetes; Postprandial Hyperglycemia and Diabetes Complications; Is It Time to Treat? Diabetes. 2005;54:1–7.PubMedCrossRef
3.
Nogueira AI, Souza Santos RA, Simões E, Silva AC, Cabral AC, Vieira RL, et al. The Pregnancy-induced increase of Plasma angiotensin (1–7) is blunted in gestational diabetes. Regulatory Peptides. 2007;141:55–60.PubMedCrossRef
4.
Schwar Peter EH, Bornstein Stefan R, Markolf H. Elevated fasting glucose levels predicts IGT and diabetes also in middle-age subjects. Diabetes research and Clinical Practice. 2006;77:148–50.CrossRef
5.
Date Y, Nakazato M, Hashiguchi S, Dezaki K, Mondal MS, Hosoda H, et al. Ghrelin is present in pancreatic alpha-cells of humans and rats and stimulates insulin secretion. Diabetes. 2002;51:124–29.PubMedCrossRef
6.
Rindi G, Necchi V, Savio A, Torsello A, Zoli M, Locatelli V, et al. Characterisation of gastric ghrelin cells in man and other mammals: studies in adult and fetal tissues. Histochem Cell Biol. 2002;117:511–19.PubMedCrossRef
7.
Salehi A, Dornonville de la Cour C, Håkanson R, Lundquist I. Effects of ghrelin on insulin and glucagon secretion: a study of isolated pancreatic islets and intact mice. Regul Pept. 2004;118:143–50.PubMedCrossRef
8.
Prodam F, Me E, Riganti F, Gramaglia E, Bellone S, Baldelli R, et al. The nutritional control of ghrelin secretion in humans: the effects of enteral vs. parenteral nutrition. Eur J Nutr. 2006;45:399–405.PubMedCrossRef
9.
Sharma M, Siddique MW, Shamim Akhter M, Gyanesh S, Pillai KK. Evaluation of Antidiabetic and Antioxidant Effects of Seabuckthorn (Hippophaerhamnoides L.) in Streptozotocin-Nicotinamide Induced Diabetic Rats. The Open Conference Proceedings Journal. 2011;2:53–8.CrossRef
10.
Wang B, Li Y, Liu X, Liu S, Sun C. Effect of the duration of high-fat diet and the dosage of streptozotocin on establishing experimental animal model of type 2 diabetes mellitus. Wei Sheng Yan Jiu. 2011;40:99–102.PubMed
11.
Murdolo G, Lucidi P, Di Loreto C, Parlanti N, De Cicco A, Fatone C, et al. Insulin is required for prandial ghrelin suppression in humans. Diabetes. 2003;52:2923–27.PubMedCrossRef
12.
Spranger J, Ristow M, Otto B, Heldwein W, Tschöp M, Pfeiffer AFH, et al. Post-prandial decrease of human plasma ghrelin in the absence of insulin. J Endocrinol Invest. 2003;26:19–22.CrossRef
13.
Caixás A, Bashore C, Nash W, Pi-Sunyer F, Laferrère B. Insulin, unlike food intake, does not suppress ghrelin in human subjects. J Clin Endocrinol Metab. 2002;87:1902.PubMedCrossRef
14.
Shiiya T, Nakazato M, Mizuta M, Date Y, Mondal MS, Tanaka M, et al. Plasma ghrelin levels in lean and obese humans and the effect of glucose on ghrelin secretion. J Clin Endocrinol Metab. 2002;87:240–44.PubMedCrossRef
15.
Briatore L, Andraghetti G, Cordera R. Acute plasma glucose increase, but not early insulin response, regulates plasma ghrelin. Eur J Endocrinol. 2003;149:403–6.PubMedCrossRef
16.
Monteleone P, Bencivenga R, Longobardi N, Serritella C, Maj M. Differential responses of circulating ghrelin to high-fat or high-carbohydrate meal in healthy women. J Clin Endocrinol Metab. 2003;88:5510–14.PubMedCrossRef
Metadaten
Titel
The effect of the intracerebroventricular injection of Ghrelin agonist on diabetes type 2 disease in male wistar rats
verfasst von
Alieh Safamanesh
Ramesh Ahmadi
Elham Safarpour Kapurchal
Arezou Ghahghaei
Publikationsdatum
01.09.2014
Verlag
Springer India
Erschienen in
International Journal of Diabetes in Developing Countries / Ausgabe 3/2014
Print ISSN: 0973-3930
Elektronische ISSN: 1998-3832
DOI
https://doi.org/10.1007/s13410-013-0165-8

Weitere Artikel der Ausgabe 3/2014

International Journal of Diabetes in Developing Countries 3/2014 Zur Ausgabe

Letter to Editor

Body mass index and random blood glucose levels in a semi urban Nigerian community

Original Article

Decreased serum monocytes and elevated neutrophils as additional markers of insulin resistance in type 1 diabetes

Original Article

Diabetic foot ulcers—where do we stand microbiologically?

Review Article

Amylin dual action: a second gluco regulatory β-cell hormone, treatment and cause for the diabetes

Original Article

Links between adiposity, physical activity and self-reported fatigue in patients with type 2 diabetes mellitus

Original Article

Evaluation of the dietary pattern of patients with type 2 diabetes in Northern Jordan: An inconvenient truth!